These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 33606996)

  • 1. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation.
    Yu M; Peng Z; Qin M; Liu Y; Wang J; Zhang C; Lin J; Dong T; Wang L; Li S; Yang Y; Xu S; Guo W; Zhang X; Shi M; Peng H; Luo X; Zhang H; Zhang L; Li Y; Yang XP; Sun S
    Mol Cell; 2021 Mar; 81(6):1216-1230.e9. PubMed ID: 33606996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
    Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
    Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNOT4 enhances the efficacy of anti-PD-1 immunotherapy in a model of non-small cell lung cancer.
    Zhang B; Han S; Ma H; Chen S
    FEBS Open Bio; 2020 Dec; 10(12):2631-2639. PubMed ID: 33034149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
    Lai Q; Wang H; Li A; Xu Y; Tang L; Chen Q; Zhang C; Gao Y; Song J; Du Z
    Oncogene; 2018 Apr; 37(17):2302-2312. PubMed ID: 29422611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m
    Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
    EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade.
    Vackova J; Piatakova A; Polakova I; Smahel M
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
    Pai CS; Huang JT; Lu X; Simons DM; Park C; Chang A; Tamaki W; Liu E; Roybal KT; Seagal J; Chen M; Hagihara K; Wei XX; DuPage M; Kwek SS; Oh DY; Daud A; Tsai KK; Wu C; Zhang L; Fasso M; Sachidanandam R; Jayaprakash A; Lin I; Casbon AJ; Kinsbury GA; Fong L
    Immunity; 2019 Feb; 50(2):477-492.e8. PubMed ID: 30737146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Cancer; 2019 Jun; 19(1):605. PubMed ID: 31221124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.
    Ni X; Tao J; Barbi J; Chen Q; Park BV; Li Z; Zhang N; Lebid A; Ramaswamy A; Wei P; Zheng Y; Zhang X; Wu X; Vignali P; Yang CP; Li H; Pardoll D; Lu L; Pan D; Pan F
    Cancer Discov; 2018 Aug; 8(8):1026-1043. PubMed ID: 29907586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy.
    Reggiani F; Gobbi G; Ciarrocchi A; Ambrosetti DC; Sancisi V
    Biochim Biophys Acta Rev Cancer; 2020 Jan; 1873(1):188341. PubMed ID: 31931113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
    J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
    Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
    EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
    Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
    FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner.
    Liu Y; Wang G; Yang Y; Mei Z; Liang Z; Cui A; Wu T; Liu CY; Cui L
    Oncogene; 2016 May; 35(21):2789-800. PubMed ID: 26387538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.